CHF Solutions’ Physician-Led Webinar Concludes Fluid Overloaded Heart Failure Patients Benefit from Ultrafiltration
September 10 2020 - 8:15AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload, today
announced key takeaways from a recent webinar, where Dr. John L.
Jefferies discussed the use of precision medicine for the treatment
of fluid overload in heart failure (HF) patients, including
alternatives to diuretics, such as ultrafiltration using the
Aquadex SmartFlow™ system.
Clinically important observations made by Dr. Jefferies during
the webinar include:
- The impact of fluid overload on HF patients is significant. 90%
of HF hospitalizations are due to signs and symptoms of fluid
overload.1
- Common fluid overload treatment approaches such as diuretics
are associated with mixed outcomes and adverse events. Studies have
shown 42% of acutely decompensated HF patients either return to the
emergency room, are re-hospitalized or die within 60 days of
hospital discharge, regardless of diuretic strategy.2
- Ultrafiltration is an effective treatment strategy for patients
with HF. When compared to diuretics, there is a 53% reduction
in the risk of rehospitalization among HF patients receiving
ultrafiltration.3
- The use of ultrafiltration after cardiac surgery has been shown
to improve cardiac performance, 4 reduce the duration of assisted
ventilation5 and can reduce the need for blood transfusions.6
“Ultrafiltration has continued to demonstrate efficacy in
various clinical settings, and heart failure is a significant area
where Aquadex™ has proven to be advantageous in the delivery of
effective patient care,” said John Erb, CEO of CHF Solutions. “Dr.
Jefferies’ experience provides valuable insights for heart failure
clinicians and beyond. There are many patients who can benefit from
ultrafiltration therapy and this educational webinar helps to
ensure providers are equipped with knowledge of various treatment
options for fluid overloaded patients.”
Dr. Jefferies also discussed Aquadex-specific considerations and
recommendations in regard to venous access, anticoagulation,
ultrafiltration rate and Hematocrit (HCT) and SV02
monitoring. Access this information and a white paper
analysis by watching the webinar replay available on the company
website and on CHF Solutions’ YouTube page. Dr. Jefferies’
presentation will be a part of the company’s offerings at the 24th
Annual Scientific Meeting of the Heart Failure Society October 3-5,
2020.
Dr. Jefferies serves as Director of the Methodist University of
Tennessee Cardiovascular Institute. He is a Professor of Pediatric
Cardiology, Professor of Preventive Medicine, and a Research Member
of St. Jude Children’s Research Hospital. Dr. Jefferies has
published 200 peer-reviewed manuscripts and is the Lead Editor for
two widely acclaimed textbooks.
About CHF Solutions
CHF Solutions, Inc. (CHFS) is a medical device company dedicated
to changing the lives of patients suffering from fluid overload
through science, collaboration, and innovation. The company is
focused on developing, manufacturing and commercializing the
Aquadex SmartFlow™ system for ultrafiltration therapy. CHF
Solutions is headquartered in Minneapolis, Minn., with wholly-owned
subsidiaries in Australia and Ireland. The company has been listed
on the Nasdaq Capital Market since February 2012.
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy
using a simple, flexible and smart method of removing excess fluid
from patients suffering from hypervolemia (fluid overload). The
Aquadex SmartFlow system is indicated for temporary (up to 8 hours)
or extended (longer than 8 hours in patients who require
hospitalization) use in adult and pediatric patients weighing 20 kg
or more whose fluid overload is unresponsive to medical management,
including diuretics. All treatments must be administered by a
health care provider, within an outpatient or inpatient clinical
setting, under physician prescription, both having received
training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements about the treatment of fluid overload in
patients with acute heart failure. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this release, including, without
limitation, those risk associated with our expectations regarding
the potential impacts of the COVID-19 pandemic on our business
operations, our ability to execute on our commercial strategy, the
possibility that we may be unable to raise sufficient funds
necessary for our anticipated operations, our post-market clinical
data collection activities, benefits of our products to patients,
our expectations with respect to product development and
commercialization efforts, our ability to increase market and
physician acceptance of our products, potentially competitive
product offerings, intellectual property protection, our ability to
integrate acquired businesses, our expectations regarding
anticipated synergies with and benefits from acquired businesses,
and other risks and uncertainties described in our filings with the
SEC. Forward-looking statements speak only as of the date when
made. CHF Solutions does not assume any obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
- Costanzo MR, et al. J Am Coll Cardiol. 2017 May
16;69(19):2428-2445
- Felker MG, et al. N Engl J Med 2011; 36:797-805.
- Costanzo MR, et al. J Am Coll Cardiol. 2007;49(6):675-683
- Sahoo, TK, et al. Indian J Thorac Cardiovas Surg. 2007
Jun;23(2): 116-124.
- Luciani GB, et al. Circulation. 2001 Sep 18;104(12 Suppl 1):
I253-I259
- Sahoo, TK, et al. Indian J Thorac Cardiovas Surg. 2007
Jun;23(2): 116-124.
CONTACTS
INVESTORS:
Claudia Napal Drayton Chief Financial Officer, CHF Solutions,
Inc. 952-345-4205ir@chf-solutions.com
MEDIA:
Jessica
StebingHealth+Commerce260-336-6202jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2024 to May 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From May 2023 to May 2024